References
- 1. F Romi, J.A.Aarli and N.E. Gilhus. Seronegative myasthenia gravis: disease severity and prognosis. European Journal of Neurology 2005; 12: 413-418.
- 2. A.Vincent, J.Bowen, J.Newsom-Davis and J.McConvillie. Seonegative generalized mysthenia gravis: clinical features, antibodies and their target. Lancet Neurology 2003; 2: 99-106.
- 3. Pevzner A, Schoser B, Peteres K, et all. Anti-LRP4 autoantibodies in AchR- and MuSK antibody negative myasthenia gravis. J Neurol 2012; 259(3): 427-35.
- 4. Liyanage Y, Hoch W, Beeson D, Vincet A. The agrin/ muscle specific kinase pathway. New target for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002; 25: 4-16.
- 5. Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010; 23: 489-495.
- 6. Chan et all. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007 36 (5):651-8
- 7. Nikolić A, Djukić P, Basta I, et all. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis. Clinical Neurol Neurosurg. 2013 115 (4):432-7
- 8. Evoli A, Tonali P, Padua L, et all. Clinical correlates with anti MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126: 2304-2311.
- 9. Kim N, Stiegler AL, Cameron TO, et all. LRP 4 is a receptor for agrin and forms a complex with MuSK. Cell 2008; 135:334-342.
- 10. Baggi F, Andereetta F, Maggi L et all. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology 2013; 8:80 (2): 188-95
- 11. Witoonpanich et all. Electrophysiological and immunological study in myasthenia gravis: diagnostic sensitivity and correlation. Clin Neurophysiol. 2011 122 (9): 1873-7
- 12. Leite MI, Jacob S, Viegas S, et all. IgG1 antibodies to acetylcholine receptors in seronegative myasthenia gravis. Brain 2008; 131: 1940-1952
- 13. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-denssity lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69: 418-422.
- 14. Simon-Chazottes D, Tutois S, Kuehn M,et all. Mutations in the gene encoding the low-density lipoprotein LRP4 cause abnormal limb development in the mouse. Genomics 2006; 87: 673-677.
- 15. Courtney M. Karner, Martin F. Dietrich, Eric B. Johnson, et all. LRP4 regulates initiation of ureteric budding and is crucial for kidney formation of the neuromuscular junction. Development 2010; 133: 4993-500
- 16. Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparasion of anti-MuSK-vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007;68:609-611